# Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients

> **NCT03184467** · PHASE2 · COMPLETED · sponsor: **GemVax & Kael** · enrollment: 96 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Normal Saline 0.9%
- **DRUG:** GV1001 0.56 mg
- **DRUG:** GV1001 1.12 mg

## Key facts

- **NCT ID:** NCT03184467
- **Lead sponsor:** GemVax & Kael
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2019-09-05
- **Final completion:** 2019-09-19
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184467, "Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03184467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*